Loading...
Bioventus Q1 2025 Earnings Report
Bioventus reported its first quarter financial results, with revenue declining 4.3% but organic revenue advancing 5.0%.
Key Takeaways
Bioventus reported a first-quarter net loss of $2.6 million, or $0.04 per share, on revenue of $123.9 million. Despite a decline in reported revenue, organic revenue increased by 5.0%. The company reiterated its full-year 2025 financial guidance.
Q1 reported revenue was $123.9 million, a 4.3% decline from the prior year.
Organic revenue advanced 5.0% due to positive organic growth across all three businesses.
Net loss was $0.04 per share, an improvement from a $0.08 loss in the prior-year period.
Non-GAAP earnings per share increased 33% to $0.08.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus reiterated its 2025 financial guidance, expecting net sales between $560 million and $570 million and Adjusted EBITDA between $112 million and $116 million.
Positive Outlook
- Net sales expected to be between $560 million and $570 million.
- Organic growth of approximately 6.1% to 8.0% included in net sales guidance.
- Adjusted EBITDA expected to be between $112 million and $116 million.
- Adjusted EBITDA Margin growth of 100 basis points compared to 2024.
- Non-GAAP EPS expected to increase by 30.6% to 38.8% ($0.64 to $0.68).
Challenges Ahead
- The guidance includes an estimated immaterial impact of tariffs.
- The company is unable to provide U.S. GAAP financial measures on a forward-looking basis due to uncertainties.
- Acquisition and divestiture related expenses are uncertain and could be material.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...